Lanifibranor and NASH resolution

Elena Kotsiliti, associate editor at Nature Reviews Gastroenterology & Hepatology, presents the results of the phase IIb NATIVE double-blind, randomized, placebo-controlled trial. This trial investigated lanifibranor (a pan-proliferator–activated receptor agonist) in patients with severe nonalcoholic steatohepatitis (NASH) without cirrhosis...
PUBLISHED IN: Nat Rev Gastroenterol Hepatol 2021

Commentary

Elena Kotsiliti, associate editor at Nature Reviews Gastroenterology & Hepatology, presents the results of the phase IIb NATIVE double-blind, randomized, placebo-controlled trial. This trial investigated lanifibranor (a pan-proliferator–activated receptor agonist) in patients with severe nonalcoholic steatohepatitis (NASH) without cirrhosis. 247 patients were randomised to receive 1,200 mg (n = 83) or 800 mg (n = 83) of oral lanifibranor or placebo (n = 81) daily for 24 weeks. “Resolution of NASH without worsening of fibrosis was observed in both lanifibranor groups compared with placebo”. “Adverse effects were similar in both treatment groups.”

Share the article
Avatar photo

Dr. G. Bozet, MD

Articles: 174

Leave a Reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES